- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03677154
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Reference Study ID Number: GO40554 https://forpatients.roche.com/
- Phone Number: 888-662-6728 (U.S. and Canada)
- Email: global.rochegenentechtrials@roche.com
Study Locations
-
-
-
Beer Sheva, Israel, 8410101
- Soroka Medical Center
-
Haifa, Israel, 3109601
- Rambam Medical Center
-
Haifa, Israel, 3436212
- Carmel Medical Center
-
Jerusalem, Israel, 9103102
- Shaare Zedek Medical Center
-
Jerusalem, Israel, 9112001
- Hadassah Ein-Karem; Clinical Pharmacology Unit
-
Kfar- Saba, Israel, 4428164
- Meir Medical Center
-
Netanya, Israel, 4215000
- Laniado Hospital-Sanz Medical Center
-
Petach Tikva, Israel, 4941492
- Rabin Medical Center-Beilinson Campus
-
Ramat Gan, Israel, 5262100
- Sheba Medical Center
-
Rehovot, Israel, 7610001
- Kaplan Medical Center
-
Tel Aviv, Israel, 6423906
- Tel Aviv Sourasky Medical Center; Pharmacy
-
-
-
-
-
Busan, Korea, Republic of, 602-739
- Pusan National University Hospital
-
Daegu, Korea, Republic of, 41931
- Keimyung University Dongsan Hospital
-
Incheon, Korea, Republic of, 21565
- Gachon University Gil Medical Center
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
Seoul, Korea, Republic of, 03722
- Severance Hospital, Yonsei University
-
Seoul, Korea, Republic of, (0)7345
- The Catholic University of Korea Yeouido St. Mary's Hospital; Hematology-Oncology
-
-
-
-
-
Gdansk, Poland
- Uniwersyteckie Centrum Kliniczne
-
Gdynia, Poland, 81-519
- Szpitale Pomorskie Sp. z o. o.
-
Kraków, Poland, 30-727
- Pratia MCM Krakow
-
Lublin, Poland, 20-090
- Centrum Onkologii Ziemi Lubelskiej im. ?w. Jana z Dukli
-
Opole, Poland, 45-372
- Szpital Wojewodzki w Opolu;Pododdz. Gastroenter., Pododdz. Hematologii
-
Warszawa, Poland, 02-776
- Instytut Hematologii i Transfuzjologii; Klinika Hematologii
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitario Vall d Hebron
-
Caceres, Spain, 10003
- Hospital San Pedro de Alcantara; Servicio de Hematología
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 28007
- Hospital General Universitario Gregorio Maranon
-
Valencia, Spain, 46026
- Hospital Universitari i Politecnic La Fe
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain, 08908
- Institut Catala d Oncologia Hospitalet
-
-
Sevilla
-
Seville, Sevilla, Spain, 41071
- Hospital Universitario Virgen Macarena
-
-
-
-
-
New Taipei City, Taiwan, 23561
- Taipei Medical University ?Shuang Ho Hospital
-
Tainan, Taiwan, 00704
- National Cheng Kung University Hospital; Oncology
-
Tainan, Taiwan, 736
- Chi-Mei Hospital, Liouying
-
Taipei, Taiwan, 10002
- National Taiwan University Hospital
-
Taipei, Taiwan, 104
- Mackay Memorial Hospital
-
Taipei City, Taiwan, 11217
- Taipei Veterans General Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- University of Alabama at Birmingham School of Medicine
-
-
California
-
Santa Monica, California, United States, 90404-2023
- University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica
-
-
Florida
-
Miami, Florida, United States, 33176
- Miami Cancer Institute of Baptist Health, Inc.
-
Miami, Florida, United States, 33136
- University of Miami Sylvester Comprehensive Center
-
Tampa, Florida, United States, 33617
- Moffitt Cancer Center Screening and Prevention
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center; Rush University Cancer Center
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46805
- Fort Wayne Medical Institute
-
-
Kentucky
-
Louisville, Kentucky, United States, 40207
- Norton Medical Plaza II; Norton Cancer Institute
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0934
- University of Michigan
-
-
New York
-
New York, New York, United States, 10065
- Sloan Kettering Cancer Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27708-9963
- Duke University
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Portland Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903-4923
- Rhode Island Hospital
-
-
Texas
-
Dallas, Texas, United States, 75246
- Texas Oncology - Baylor Charles A. Sammons Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for All Cohorts
- At least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest diameter
- Adequate hematologic function
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2; with the exception of South Korea, where participants 80 years or older with ECOG >/= 2 will not be eligible
Inclusion Criteria Specific to Cohort A
Participants in Cohort A must also meet the following criteria for study entry:
- Histologically confirmed DLBCL according to World Health Organization (WHO) 2016 expected to express the cluster of differentiation-20 (CD20) antigen
- One prior therapy with any systemic anthracycline-based chemoimmunotherapy containing regimen for previously untreated DLBCL
- Best response of SD or PR to prior systemic chemoimmunotherapy at the end of induction treatment in accordance with the Lugano 2014 criteria
Inclusion Criteria Specific to Cohorts B and C
Participants in Cohorts B and C must also meet the following criteria for study entry:
- Previously untreated, histologically confirmed, DLBCL according to WHO 2016 classification
- Age >/= 80 years, or
- Age 65-79 years and considered ineligible for chemoimmuotherapy (R-CHOP) with at least one of the following: Impairment in at least two activity of daily living (ADL) components as defined in the protocol; impairment in at least two instrumental ADL components as defined in the protocol; cumulative illness rating scale - geriactic (CIRS-G) score of at least one cormorbidity with a severity score of 3-4 (not including lymphoma and hematologic deficiencies due to lymphoma) or a score of 2 in >/= 8 comorbidities; impairment in cardiac function, renal function, liver function, or other comorbidities such that the participant is unfit for full-dose immunochemotherapy, such as rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)
- Participants with an initial ECOG performance status of 3 may be considered during screening if the performance status is DLBCL-related and if pre-phase treatment during the screening phase (not more than 100 mg/day up to 7 days prior to Cycle 1 Day 1) results in an improvement of ECOG performance status to </= 2 prior to enrollment
Exclusion Criteria for All Cohorts
Participants who meet any of the following criteria will be excluded from study entry:
- Transformed lymphoma
- CNS lymphoma
- Prior treatment with mosunetuzumab
- Prior stem cell transplant (autologous and allogeneic)
- History of confirmed progressive multifocal leukoencephalopathy (PML)
- Known or suspected chronic active Epstein Barr virus (CAEBV), hepatitis B, hepatitis C (HCV), or Human Immunodeficiency Virus (HIV)
- Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
- Positive SARS-CoV-2 antigen or PCR test within 30 days prior to Cycle 1 Day 1
- Prior solid organ transplantation
- Current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
- Clinically significant history of liver disease
- Prior treatment with radiotherapy within 2 weeks prior to Cycle 1, Day 1 (C1D1)
- Significant cardiovascular disease
Exclusion Criteria Specific to Cohort A
Participants in Cohort A who meet the following criteria will be excluded from study entry:
- Prior anti-lymphoma treatment with chemotherapy, immunotherapy, or biologic therapy 4 weeks prior to C1D1
Exclusion Criterion Specific to Cohorts B and C
Participants in Cohorts B and C who meet the following criterion will be excluded from study entry:
- Prior treatment for DLBCL with chemotherapy, immunotherapy, and biologic therapy
Exclusion Criteria Specific to Cohort C
Participants in Cohort C who meet the following criteria will be excluded from study entry:
- Current Grade >1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Consolidation Therapy (Cohort A)
Participants with a partial response to first-line chemotherapy will receive mosunetuzumab up to the recommended consolidation dose (RCD).
|
Participants in cohorts A and B will receive IV mosunetuzumab.
Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).
|
Experimental: Elderly/Unfit Previously Untreated Monotherapy (Cohort B)
Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab at the previously determined recommended phase II dose (RP2D).
|
Participants in cohorts A and B will receive IV mosunetuzumab.
Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).
|
Experimental: Elderly/Unfit Previously Untreated Combination Therapy (Cohort C)
Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab in combination with polatuzumab vedotin.
|
Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).
Participants in Cohort C will receive SC mosunetuzumab.
Participants in Cohort C will receive IV polatuzumab vedotin.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants with Adverse Events
Time Frame: Baseline through approximately 90 days after last study treatment
|
Baseline through approximately 90 days after last study treatment
|
Positron Emission Tomography-Computed Tomography (PET-CT) Complete Response (CR) Rate at Time of Primary Response Assessment (PRA) According to Lugano 2014 Response Criteria (Cohort A)
Time Frame: 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
|
6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
|
PET-CT Objective Response Rate (ORR) at PRA According to Lugano 2014 Response Criteria as Determined by the Investigator (Cohort B)
Time Frame: 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
|
6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
|
PET-CT ORR at PRA According to the Lugano 2014 Criteria as Determined by an Independent Review Committee (IRC) (Cohort C)
Time Frame: 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
|
6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum Serum Concentration (Cmax) of Mosunetuzumab IV
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Minimum Serum Concentration (Cmin) of Mosunetuzumab IV
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Area Under the Curve (AUC) of Mosunetuzumab IV
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Clearance (CL) of Mosunetuzumab IV
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Volume of Distribution at Steady State (Vss) of Mosunetuzumab IV
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Maximum Serum Concentration (Cmax) of Mosunetuzumab SC
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Time to Maximum Serum Concentration (Tmax) of Mosunetuzumab SC
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Minimum Serum Concentration (Cmin) of Mosunetuzumab SC
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Area Under the Curve (AUC) of Mosunetuzumab SC
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Clearance (CL) of Mosunetuzumab SC
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Volume of Distribution at Steady State (Vss) of Mosunetuzumab SC
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Maximum Serum Concentration (Cmax) of Polatuzumab Vedotin IV
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Minimum Serum Concentration (Cmin) of Polatuzumab Vedotin IV
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Area Under the Curve (AUC) of Polatuzumab Vedotin IV
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Clearance (CL) of Polatuzumab Vedotin IV
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Volume of Distribution at Steady State (Vss) of Polatuzumab Vedotin IV
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
End of Infusion Concentration (Ceoi) of Polatuzumab Vedotin IV
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Trough Concentration (Ctrough) of Polatuzumab Vedotin IV
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
PET-CT Rate According to the Lugano 2014 Criteria at PRA as Determined by the Investigator (Cohorts B and C) and IRC (Cohort C)
Time Frame: 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
|
6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
|
Objective Response Rate (ORR), Defined as the Proportion of Participants with a Complete Response (CR) or Partial Response (PR) at PRA as Determined by the Investigator (Cohorts A and C)
Time Frame: Baseline through 2 years after PRA (up to a total of approximately 2.5 years)
|
Baseline through 2 years after PRA (up to a total of approximately 2.5 years)
|
Best ORR (CR or PR at any time) During the Study Based on PET-CT and/or CT Scans as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)
Time Frame: Baseline through 2 years after PRA (up to a total of approximately 2.5 years)
|
Baseline through 2 years after PRA (up to a total of approximately 2.5 years)
|
Duration of Response (DOR) as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)
Time Frame: From the first occurrence of a documented objective response to disease progression, relapse, or death, whichever occurs first (up to approximately 2.5 years)
|
From the first occurrence of a documented objective response to disease progression, relapse, or death, whichever occurs first (up to approximately 2.5 years)
|
Duration of Confirmed Response (DOCR) as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)
Time Frame: From the first occurrence of a documented CR to disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 2.5 years)
|
From the first occurrence of a documented CR to disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 2.5 years)
|
Progression-Free Survival (PFS) as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)
Time Frame: From the first study treatment to the first occurrence of disease progression, relapse, or death, whichever occurs first (up to approximately 2.5 years)
|
From the first study treatment to the first occurrence of disease progression, relapse, or death, whichever occurs first (up to approximately 2.5 years)
|
Overall Survival (OS)
Time Frame: From the first study treatment to death from any cause
|
From the first study treatment to death from any cause
|
Time to Deterioration in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Physical Functioning and Fatigue (Cohorts B and C)
Time Frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
|
From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
|
Time to Deterioration in European Organization for Research and Treatment of Cancer Item Library (EORTC-IL17) Physical Functioning (Cohorts B and C)
Time Frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
|
From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
|
Time to Deterioration in the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale (Cohorts B and C)
Time Frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
|
From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
|
Proportion of Participants Achieving a Clinically Meaningful Improvement in Physical Functioning as Measured by EORTC QLQ-C30 (Cohorts B and C)
Time Frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
|
From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
|
Proportion of Participants Achieving a Clinically Meaningful Improvement in Physical Functioning as Measured by EORTC IL17 (Cohorts B and C)
Time Frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
|
From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
|
Anti-Drug Antibodies (ADAs) to Mosunetuzumab
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin (Cohort C)
Time Frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Physiological Effects of Drugs
- Immunologic Factors
- Immunoconjugates
- Polatuzumab vedotin
Other Study ID Numbers
- GO40554
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Large B-cell Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on Mosunetuzumab Intravenous (IV)
-
Genentech, Inc.Active, not recruitingLymphocytic Leukemia, Chronic | Lymphoma, Non HodgkinUnited States, Korea, Republic of, Australia, United Kingdom, Germany, Canada, Spain
-
Hoffmann-La RocheActive, not recruitingB-cell Non-Hodgkin LymphomaUnited States, Canada, Belgium, Spain, United Kingdom
-
Hoffmann-La RocheActive, not recruitingFollicular LymphomaUnited Kingdom, United States, China, France, Spain
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Follicular LymphomaUnited States
-
Genentech, Inc.RecruitingNon-Hodgkin LymphomaUnited States, Puerto Rico
-
Suvankar MajumdarCompletedSickle Cell DiseaseUnited States
-
Hoffmann-La RocheRecruitingSystemic Lupus ErythematosusUnited States, Poland, Ukraine, Georgia, Moldova, Republic of
-
M.D. Anderson Cancer CenterGenentech, Inc.WithdrawnRefractory B-cell Acute Lymphoblastic LeukemiaUnited States
-
Singapore General HospitalSingapore Civil Defence ForceCompleted
-
Weill Medical College of Cornell UniversityEpizyme, Inc.; Genentech, Inc.Recruiting